Award schedule

NHS National Pharmaceuticals - Lenalidomide

Offer reference number: CM/PHG/21/5638

01/09/2022 to 31/08/2023 (12 months) with an option or options to extend (at the Authority's discretion) for a agreement: period or periods up to a total of 48 months. Potential periods of call-offs under the framework agreement: ALL REGIONS: Lenalidomide - 01/09/2022 to 31/08/2023 (12 months)
Shared Award

SUPPLIER NAME: Glenmark Pharmaceuticals Europe Limited

All the products listed below are Subject to QC

NPC	Description	Pack	QA Risk Category Offe E - Elevated Paci	Brand	EAN Code	Product Licence no. or date expected	List Price	quantitiv	include patient	a nanor-based	NHS Stores discoun	Product(s) registered on PharmaQC?* (Yes/No)	Pharmage 2*	Dy WHKA?	If PPP not yet approved by MHRA state expected date	PPP format - Select Digital** /Paper/Both	Will your PPP be provided via the BGMA portal when available?
DHA385	Lenalidomide 10mg capsules	21	21		5060204166761	25258/0338											
DHA386	Lenalidomide 15mg capsules	21	21		5060204166778	25258/0339											
DHK053	Lenalidomide 20mg capsules	21	21		5060204166785	25258/0340						Redacted ·	- Section 43				
DHB148	Lenalidomide 25mg capsules	21	21		5060204166792	25258/0341											
DHA384	Lenalidomide 5mg capsules	21	21		5060204166754	25258/0337											

*Products must be registered and artwork/ documents uploaded onto PharmaQC for an award to be made

** A digital portal is a secure cloud based portal that allows electronic capture and approval of patient authorisation forms.

Additional information

Delivery	
Direct - please	
state contact	
details	
Direct/and or	
Distributor	
Distributor -	
Please list	
Delivery	
charges	Redacted - Section 43
Minimum order	
value	
Delivery	
charges	
E-ordering	
(Yes/No)	
E-Invoicing	
(Yes/No)	
Tender contact	
details	
First name	
Surname	
Email	Redacted - Section 43
Telephone	
Fax	